Asia Pacific : Japan Healthcare Outlook 2010

P3B5-54

April 2010

Asia Pacific Healthcare Outlook

Focus : JapanAnalysis of Best Opportunities

2P3B5-54

Disclaimer

• Frost & Sullivan takes no responsibility for the incorrect information supplied to us by manufacturers or users.

• Quantitative market information is based primarily on interviews and therefore, is subject to fluctuation.

• Frost & Sullivan Research Services are limited publications containing valuable market information provided to a select group of customers in response to orders. Our customers acknowledge, when ordering, that Frost & Sullivan Research Services are for customers’ internal use and not for general publication or disclosure to third parties.

• No part of this Research Service may be given, lent, resold, or disclosed to non-customers without written permission.

• Furthermore, no part may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the permission of the publisher.

• For information regarding permission, write to:

Frost & Sullivan GIC Malaysia Sdn. Bhd.

Suite E-08-15, Block E

Plaza Mont’ Kiara

2 Jalan Kiara, Mont’ Kiara

50480 Kuala Lumpur.

© 2010 Frost & Sullivan. All rights reserved. This document contains highly confidential information and is the sole property of Frost & Sullivan. No part of it may be circulated, quoted, copied or otherwise reproduced without the written approval of Frost & Sullivan.

3P3B5-54

Certification

• We hereby certify that the views expressed in this research service accurately reflect our views based on primary

and secondary research with industry participants, industry experts, end users, regulatory organizations, financial

and investment community, and other related sources.

• In addition to the above, our robust in-house forecast & benchmarking models along with the Frost & Sullivan

Decision Support Databases have been instrumental in the completion and publishing of this research service.

• We also certify that no part of our analyst compensation was, is or will be, directly or indirectly, related to the

specific recommendations or views expressed in this research service.

4P3B5-54

TABLE OF CONTENT

1. Overview of Healthcare Market : Key Takeaways

• Setting the Scene: Outlook for Healthcare Industry from 2010-12

• Global vs. APAC: The New Frontier

2. In-depth Sectoral Analysis, APAC and Japan

• APAC Pharmaceuticals & Biotechnology Market

• Japan Pharmaceuticals & Biotechnology Market

• Top Growth Opportunities : Japan Pharmaceuticals and Biotech Market

• APAC Medical Equipment Market

• Japan Medical Equipment Market

• Top Growth Opportunities : Japan Medical Equipment Market

• APAC Lifesciences and Health IT Market

• Japan Health IT Market

• Top Growth Opportunities : Japan Health IT Market

3. Summary : Best Opportunity Analysis, APAC and Japan

• Where to place your bets in APAC: 2010- 2012

• Where to place your bets in Japan: 2010- 2012

5P3B5-54

TABLE OF CONTENT

4. Decision Support Database

• Total Health Expenditure

• Private Health Expenditure

• Government Health Expenditure

• Percent Healthcare Expenditure in GDP

• Population Aged Above 65

5. About Frost & Sullivan

6

Overview of Healthcare Market : Key Takeaways

7P3B5-54

Setting the Scene Outlook for Healthcare Industry from 2010-12

Global Healthcare Market : 2009

• US and Europe were impacted in a major way by global crisis

• Asia also slowed down but not as much as the West

• Valuations were low and M&A was high, many smaller Biotech companies struggled

• Major organizational restructuring occurred, along with portfolios being reassessed

Global Healthcare Market : 2010-12

• Recovery of the markets to a large extent with strong growth in Asia

• Start of major patent expiries

• M&A activity down in the West but could be important in Asia, restructuring will continue

• Asia becoming increasingly important as a market and outsourcing hub

• 5Ps to drive market: Preventive, Preemptive, Personalized, Predictive, Personal Responsibility

Source: Frost & Sullivan.

8P3B5-54

Global vs. APAC: The New FrontierBy 2012 APAC expected to be close to 27% of global market

Source: Frost & Sullilvan ,2010)

23.9%23.9%

27.2%27.2%

23.2%23.2%

26.4%26.4%

CAGR12.2%CAGR12.2%

CAGR6.47%CAGR6.47%

Global & APAC Healthcare Revenues US$ Bn, 2009-2012

• By 2015 APAC could represent ~40% of global market!

Source: Frost & Sullivan

Rest of the World

APAC

9P3B5-54

Asia is however transitioningMoving toward a Multi–Polar World Order

Source: Frost & Sullilvan ,2010)

Asia Pacific Market : 2009

• Slowing down of GDP in mature markets – Japan and Australia took a big hit

• Global consolidation left a difficult mess for integration on a local level – job losses and portfolio realignment

• Price cutting and playing the margins game

• The bubble burst for Medical Tourism

• Asia started to set up infrastructure for offshoring and outsourcing for US/EU companies

Asia Pacific Market : 2012

• A shift in the center of the world economically and strategically to Asia

• Asia to move from export led development to consumption led growth

• APAC the fastest growing pharma market and API production hub

• Increased government attention to primary and community based healthcare.

• Increased use of mobile technology in healthcare service delivery

• 2010 : Malaysia Innovation and Creativity year


10P3B5-54

Aged Population , 65+ cohort is more than 20%(2008) Japan Household Financial Assets ~ US $ 16 Trillion

(Sept. 2009) **

*Source MHLW, METI

Source: Diabetes Australia

Japan-Aging Society, Increased Economic WealthSeizing Growth Opportunity in a deflationary environment

WATAMI GROUP COMMONS 30 FUND

11P3B5-54

Source: Frost & Sullivan.Source: Frost & Sullivan.

– Universal Mandatory Insurance

– Healthcare expenditure lower

compared to OECD countries

– Highly developed infrastructure

and well trained & dedicated medical staff

– Universal Mandatory Insurance

– Healthcare expenditure lower

compared to OECD countries

– Highly developed infrastructure

and well trained & dedicated medical staff

– Focus on short term cost constraint rather

than value for patients

– Duplication and fragmentation of services

–-Multi tiered distribution system

–Slow registration/approval process

– Focus on short term cost constraint rather

than value for patients

– Duplication and fragmentation of services

–-Multi tiered distribution system

–Slow registration/approval process

– Rapidly Aging Population

– Increasing economic wealth

–Low custom duties/tariffs

–Inadequate services in rural areas

– Rapidly Aging Population

– Increasing economic wealth

–Low custom duties/tariffs

–Inadequate services in rural areas

– Inefficient Physician usage

– Dependency on imports slows down

innovation

–Failure to adopt locally developed

principles like TQM

– Inefficient Physician usage

– Dependency on imports slows down

innovation

–Failure to adopt locally developed

principles like TQM

WeaknessesStrengths

Opportunities Threats

Patient Adherence(Role of New Therapies)

Re-imbursement based On value(Role of cost-effective devices)

Provider focus in under-served areas(Role of IT)

Japan Healthcare Industry –SWOT AnalysesEmerging Paradigms

12

In-depth Sectoral Analysis, APAC and South Korea

13P3B5-54

APAC Pharmaceuticals MarketEarlier diagnosis improves disease management and length of therapy

Note: All figures are rounded; the base year is 2009. Source: Frost and SullivanNote: All figures are rounded; the base year is 2009. Source: Frost and Sullivan

Market Drivers

Market Restraints

Long term use of multiple and specialized drugs for the ageing population

Government support for generics and biosimilars

Enhanced diagnosis and management in oncology, cardiovascular, pain etc

Unresolved political and regulations issues Quality concern of generics & counterfeits

Government tenders favour local manufacturers

24.6% 28.5%

CAGR6.6 %

CAGR6.6 %

CAGR12.9 %CAGR12.9 %

Pharma Revenues, US$ Bn, 2009-2012

APAC Share

750825 866 909


14P3B5-54

Japan Pharmaceuticals & Biotech MarketEnrichment of Pipeline and Diversification by M&A Activities

89 97106

115

0102030405060708090

100110120

2009 2010 2011 2012

CAGR ~8.9%

Pharma & Biotech Revenues, US$ Bn, 2009-2012 Market Drivers

Market Restraints

• Lowered profits for branded and generic drugs owing to regular price reviews

•M&A challenges

•Patent Expiration Problems

• Growing demand for lifestyle diseases drugs e.g. hypertension ,diabetes, oncology, anti-infectives• Industry’s commitment to develop biosimilars• Strong commitment and investment in R&D.


15P3B5-54

Cardiovascular disorders, alimentary canal & metabolism and general anti-infectives remained the top selling therapeutic categories in Japan, registering 2008 sales of $14.6bn, $9.6bn and $6.5bn respectively.

Prevalence of diabetes : 2010 : ~8 mn. Potential for diagnosis and treatment as nearly 20% of cases are undiagnosed

Japan generics market 2010 : ~ US$ 4 bn; CAGR ~ 10%

0

0

Bio-pharmaceuticals,

Vaccines

Bio-pharmaceuticals,

Vaccines

Cardiovascular and metabolic

diseases, Generics

Cardiovascular and metabolic

diseases, Generics

Oncology Oncology

Japan Oncology market in 2009 : ~ US$ 1 0 Billion; CAGR ~ 14-15%

Growth from early diagnosis of cancers and specialised therapies

Targeted therapies (Avastin etc)

Adjuvant therapies (Xeloda etc)

Supportive therapies (Neutrogin etc)

Top Growth Opportunities : Japan Pharmaceuticals and Biotech Market

2009 : biopharmaceuticals identified as a growth engine for the Japanese pharma sector. Targeted therapies and antineoplastics & immunomodulating agents are expected to record the highest growth with CAGR of 19.8% and 10.1%, respectively, over the forecast period.

Somatropin BS formed the first biosimilar to launch in Japan. Cervarix, Prevenar and Januvia formed the most awaited vaccine drugs to receive Japanese approval in 2009.

Vaccines offer tremendous potential (MMR, Inactivated Polio, Rotavirus). 4% of global sales.


16P3B5-54

APAC Medical Equipment MarketTransition to a mindset of monitoring

Medical Equipment Revenues, US$ Bn, 2009-2012

59.4

65.472.0

79.4


Market Drivers

• Safety, accuracy, efficiency, cost

• Automation and integration with information systems

•Emphasis on early detection and monitoring

•Silver industry requirements

Market Restraints

• Regulatory and reimbursement hurdles

• Inadequate distribution networks

• Inadequate training on and compliance to new technology


17P3B5-54

Japan Medical Equipment MarketFocus on technology that provides integrated medical care

Medical Equipment Revenues, US$ Bn, 2009-2012

Market Drivers

Market Restraints

• Demand for advanced and innovative medical equipment

• Ageing population

•Increased prevalence of chronic and lifestyle diseases

• Increasing Funding Gap (~US$ 200 Billion by 2020?)

• Strong reliance on imports in relation to domestic manufacture

• High currency fluctuations

28.2 30.2 32.3 34.5

3.73.8

3.94.0

4.14.1

4.03.9

0

5

10

15

20

25

30

35

40

45

2009 2010 2011 2012

Medical Device Medical Imaging Clinical Diagnostics

CAGR3.6%

CAGR3.6%

35.837.9

40.2 42.7


18P3B5-54

Source: Diabetes Australia

Integrated Medical Care: De Facto Standard in Not-for-Profit HospitalsContribution of Advanced Technology to Cancer Patients


19P3B5-54

Increased demand for POCT and laboratory automation products

Demand for Diabetes management tests, HbA1c, heart failure detection BNP, including NT-proBNP and lipid metabolism management index LDL-C has been increasing steadily. Influenza test kit was in enormous demand in 2009

Demand for personalized medicine/testing has started to ramp up

0

0

Top Growth Opportunities : Japan Medical EquipmentMarket

General Surgery General Surgery

Clinical Diagnostics

Clinical Diagnostics

Medical Imaging Medical Imaging

Growth in High end Surgical Planning, Simulation & Image Guided as consumers demand personalized treatment and services

Mandatory wellness checks and screening boosts CR & DR, CTA & MRA devices Shortage of Radiologists drive thin client technology, advanced image processing tools


Demand for Orthopedic, Gastro-intestinal, Urology, Cardiovascular, Neurosurgery and Pulmonary devices is being driven by increased prevalence of chronic and age related diseases .

Demand for devices used in ICU and related departments is growing at a slower place (bed penetration is less than 1%)

20P3B5-54


*Healthcare IT includes: Software, Hardware, IT services and Lifesciences IT

Asia Pacific Lifesciences and Health IT Market*Interoperability challenges hinder adoption

14.5%14.5%

15.7%15.7%

Market Drivers

Market Restraints

Operational efficiency Strong and sustained demand for healthcare services

Consumer demand for quality and access to information

Interoperability

Integration

Lack of skilled resources

Lifesciences & Healthcare IT, US$ Bn, 2009-2012

CAGR7%

CAGR7%

CAGR11.3%CAGR11.3%

APAC Share

50.654.6

58.4 62.5


21P3B5-54

Japan Health IT MarketEMR/EHR fast becoming the norm

Health IT Revenues, US$ Bn, 2009-2012

*Health IT includes: Software, Hardware, IT services, Networking

Market Drivers

•Several Government initiatives Eg. e-Japan Strategy All medical institutions are obligated to adopt this online claim system by 2011.

• Both Ministry of Health, Labor and Welfare and Ministry of Economy, Trade and Industry (METI) under pressure to aggressively coordinate HER initiatives among hospitals and clinics in each region.

Market Restraints

• Insufficient regulation on free-standing providers

• Lack of standards and interoperability

•Immense customization required to map individual hospital clinical workflows

1.51 1.52 1.6 1.65

0

0.4

0.8

1.2

1.6

2

2009 2010 2011 2012

CAGR 2.8%


22P3B5-54

0

0

0Electronic Health

RecordElectronic Health

Record

Materials Management,

Asset Tracking Solution

Materials Management,

Asset Tracking Solution

TelemedicineTelemedicine

Top Growth Opportunities : Japan Health IT Market

Japan market 2010 (Materials Mgmt) : ~US$ 200 mn; CAGR ~5%

Growing demand for patient centered healthcare services and systemized healthcare organization management through the implementation of advanced healthcare systems

Japan market 2010 (Outreach and Remote care delivery: Home Health and Tele-Medicine/Tele-Health) : ~US$ 134 mn; CAGR ~2%

The popularity of this segment can be contributed to the aging population, lack of hospital bed capacity and the increased need for home care for patients with chronic conditions. The country is also encouraging initiatives to increase communication between physician, pharmacies and patient for delivery of orders, prescriptions and payment.


Japan market 2010 (EHR) : ~US$ 600 mn; CAGR ~ 3.5%

Japan is moving towards a government-centered EHR system. The installation of EHR systems, especially for clinical use such as medical digital imaging reference functions are increasing in clinics and hospitals.

23

Summary : Best Opportunity Analysis APAC and South Korea

24P3B5-54

Co-existing Customer Segments


25P3B5-54

Where to place your bets in Japan : 2010- 2012


Time

Gro

wth

Generics

Personalised Testing

EMR/EHR

Medical Imaging(CRA, MRA etc)

INNOVATIONTRIGGER

SUPERGROWTH

NORMALISATION LEADERSHIP

Vaccines

General Surgery

CardiovascularDrugs

AdvancedImageProcessing

SurgicalPlanning

OncologyDrugs

26

Decision Support Database

• Total Health Expenditure

• Private Health Expenditure

• Government Health Expenditure

• Percent Healthcare Expenditure in GDP

• Population Aged Above 65

27P3B5-54

Decision Support Databases

Decision Support DatabaseTable Total Healthcare Expenditure (Bn USD)

Region / Country 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012CAGR %

(2005 - 2012)North America

Canada 73.0 87.8 101.2 116.9 129.5 138.3 147.0 155.2 163.0 169.8 175.9 6.00United States 1,559.0 1,678.9 1,804.7 1,936.6 2,077.5 2,232.9 2,399.2 2,573.3 2,753.9 2,944.2 3,146.3 7.18

TOTAL 1,632.0 1,766.6 1,905.9 2,053.5 2,207.0 2,371.2 2,546.3 2,728.6 2,916.8 3,114.0 3,322.1 7.11

Latin America

Argentina 11.5 14.7 17.3 20.9 23.3 25.7 27.8 29.9 31.8 33.7 35.5 7.85Brazil 40.7 45.8 55.6 74.0 78.8 83.8 90.0 97.0 104.9 113.7 123.6 7.60Chile 3.8 4.4 5.8 7.0 8.0 9.0 9.9 10.8 11.8 12.8 13.8 10.17Mexico 59.6 58.5 62.2 72.3 78.8 84.7 91.0 97.5 104.0 110.4 116.7 7.08Peru 2.4 2.7 3.1 3.6 3.9 4.2 4.5 4.9 5.2 5.6 5.9 7.46Venezuela 4.7 4.7 6.2 7.2 8.2 9.3 10.5 11.8 13.4 15.3 17.7 13.82

TOTAL 122.7 130.8 150.2 185.0 200.9 216.7 233.8 251.8 271.1 291.5 313.2 7.81

Asia - Pacific

Australia 39.4 51.0 62.4 69.9 74.7 79.9 85.1 90.4 95.9 101.4 107.1 6.29China 71.9 84.3 98.7 116.0 134.3 152.9 172.5 193.7 217.0 242.5 270.7 12.87Hong Kong 9.4 9.5 10.0 10.9 11.9 13.0 14.1 15.5 16.9 18.5 20.3 9.25India 27.5 36.1 41.9 48.5 54.0 59.8 66.1 72.8 80.0 87.5 95.5 10.16Indonesia 6.4 8.0 8.8 9.3 10.6 12.0 13.5 15.3 17.3 19.6 22.2 13.15Japan 315.4 339.5 374.9 379.7 394.0 406.6 414.7 424.9 437.0 451.7 467.5 3.02Malaysia 3.6 4.0 4.6 5.2 5.9 6.7 7.6 8.6 9.6 10.8 11.9 12.66New Zealand 5.1 6.7 8.5 9.4 10.4 11.4 12.3 13.1 13.8 14.4 14.9 6.77Philippines 2.3 2.3 2.5 2.8 3.2 3.6 4.0 4.4 4.9 5.5 6.0 11.45Singapore 3.7 4.0 4.3 4.6 5.0 5.3 5.7 6.2 6.6 7.1 7.6 7.46South Korea 25.3 30.1 33.9 39.3 43.3 47.7 52.2 56.7 61.2 66.0 70.9 8.81Taiwan 16.9 17.8 19.2 21.0 22.8 24.7 26.5 28.2 30.0 31.8 33.6 6.92Thailand 7.8 8.5 9.6 10.7 11.9 13.3 14.8 16.6 18.7 21.1 23.8 12.18

TOTAL 534.6 601.6 679.2 727.3 781.9 836.8 889.1 946.3 1,008.8 1,077.7 1,152.0 6.79

28P3B5-54

Decision Support Databases (Contd…)



(2005 - 2012)Western Europe

Austria 15.3 19.2 22.1 23.1 24.0 24.8 25.7 26.5 27.2 27.9 28.5 3.04Belgium 22.6 29.3 34.0 35.8 37.4 38.9 40.3 41.6 42.9 44.1 45.3 3.40Denmark 15.2 19.2 22.2 23.4 24.4 25.4 26.4 27.4 28.3 29.3 30.3 3.78Finland 9.5 11.8 13.6 14.4 15.1 16.0 16.9 17.7 18.5 19.3 20.1 4.90France 139.0 176.8 205.6 217.9 228.6 239.0 249.3 259.1 268.4 277.8 286.6 3.99Germany 211.1 258.9 294.6 305.9 314.9 323.7 332.6 341.2 349.3 358.1 366.6 2.62Greece 13.0 17.2 19.6 22.3 23.9 25.4 27.0 28.6 30.2 31.8 33.4 5.99Iceland 0.8 1.1 1.3 1.6 1.8 2.0 2.1 2.3 2.4 2.6 2.7 7.80Ireland 9.7 12.8 15.4 16.3 17.9 19.3 20.8 22.3 23.8 25.3 26.8 7.43Italy 99.6 122.3 139.7 143.4 149.1 154.0 159.0 163.8 168.1 172.0 175.4 2.92Luxembourg 1.5 1.9 2.3 2.5 2.7 2.8 2.9 3.0 3.2 3.3 3.4 4.14Netherlands 39.0 50.4 58.1 60.6 63.8 66.2 68.7 71.1 73.3 75.5 77.6 3.59Norway 18.3 22.7 26.1 30.4 32.5 34.7 36.9 39.3 41.4 43.4 45.5 5.94Portugal 11.3 14.3 16.5 17.3 18.2 19.1 20.0 20.9 21.9 22.8 23.8 4.60Spain 49.7 65.0 77.1 88.4 94.4 100.2 106.1 112.1 117.6 123.2 128.1 5.45Sweden 22.2 28.4 33.5 34.1 35.6 37.1 39.2 41.4 43.9 46.6 49.7 5.53Switzerland 29.7 37.0 41.5 43.1 45.7 48.4 51.1 53.8 56.5 59.3 62.2 5.39United Kingdom 121.0 141.5 170.0 180.7 191.9 203.3 214.8 227.0 238.7 250.4 262.6 5.49

TOTAL 828.6 1,029.6 1,193.2 1,261.1 1,321.7 1,380.3 1,439.8 1,499.0 1,555.5 1,612.8 1,668.5 4.08

Eastern Europe

Czech Republic 5.0 6.8 7.5 9.0 9.9 10.8 11.7 12.7 13.6 14.5 15.5 8.03Hungary 4.9 6.9 8.6 9.6 10.8 11.8 12.9 13.9 14.9 15.9 16.8 8.23Poland 12.5 13.6 15.2 17.9 19.7 21.2 22.9 24.7 26.5 28.2 29.8 7.59Russia 21.3 26.2 32.6 38.2 43.7 48.8 53.9 58.7 63.4 67.9 72.2 9.51Turkey 11.6 15.8 19.7 26.0 28.6 31.5 34.0 36.4 39.0 41.2 43.3 7.55

TOTAL 55.4 69.3 83.6 100.8 112.6 124.1 135.3 146.4 157.3 167.7 177.6 8.43

29P3B5-54




(2005 - 2012)Middle East & Africa

Egypt 4.0 3.5 3.7 4.4 5.5 6.5 7.5 8.5 9.7 11.0 12.4 16.03Israel 9.0 9.7 10.4 11.0 11.8 12.5 13.2 14.2 15.3 16.5 17.8 7.05Saudi Arabia 7.9 8.8 9.6 10.4 11.2 11.8 12.4 13.0 13.6 14.2 14.8 5.13South Africa 9.1 13.6 20.0 19.6 20.5 21.6 22.7 23.9 25.2 26.7 28.4 5.50

TOTAL 30.0 35.5 43.6 45.4 49.0 52.4 55.8 59.6 63.7 68.3 73.4 7.11

WORLD TOTAL 3,203.3 3,633.5 4,055.6 4,373.0 4,673.2 4,981.4 5,300.0 5,631.6 5,973.3 6,331.9 6,706.8 6.30

Note: All figures are rounded; the base year is 2005. Source: Frost & SullivanDefinition

Note1. Figures for 2005 are Frost & Sullivan estimates

The above figures indicate health care expenditure

Source: Frost & SullivanSource: Frost & Sullivan

30P3B5-54


Decision Support DatabaseTable Private Healthcare Expenditure (Bn USD)



Canada 22.2 26.2 30.5 35.6 39.7 42.6 45.5 48.3 50.8 53.1 55.2 6.48United States 841.0 913.2 980.5 1,045.3 1,078.0 1,155.7 1,240.9 1,330.0 1,421.0 1,517.4 1,614.5 6.41

TOTAL 863.2 939.4 1,011.0 1,080.8 1,117.7 1,198.3 1,286.4 1,378.2 1,471.9 1,570.5 1,669.7 6.41

Latin America


TOTAL 66.4 71.0 81.4 100.5 109.8 118.6 128.0 137.9 148.4 159.5 171.3 7.92

Asia - Pacific


TOTAL 177.0 204.7 235.1 264.9 293.2 320.2 345.1 372.0 401.5 435.7 472.6 8.62

31P3B5-54






TOTAL 208.8 262.0 302.3 319.3 331.4 345.0 358.5 371.7 382.7 394.2 404.7 3.45

Eastern Europe


TOTAL 18.8 23.5 28.7 34.8 39.0 43.2 47.4 51.4 55.4 59.2 62.9 8.84

32P3B5-54






TOTAL 14.0 16.7 22.0 23.1 25.2 27.3 29.3 31.6 34.1 36.9 40.0 8.17

WORLD TOTAL 1,348.2 1,517.3 1,680.4 1,823.3 1,916.3 2,052.5 2,194.7 2,342.7 2,493.8 2,655.8 2,821.2 6.43



Figures in the table represents private health expenditure


33P3B5-54


Decision Support DatabaseTable Government Healthcare Expenditure (Bn USD)



Canada 50.8 61.6 70.7 81.4 89.8 95.7 101.5 107.0 112.1 116.7 120.7 5.79United States 718.0 765.7 824.2 891.3 999.5 1,077.2 1,158.4 1,243.4 1,332.9 1,426.8 1,531.8 8.04

TOTAL 768.8 827.3 895.0 972.7 1,089.3 1,172.9 1,259.9 1,350.3 1,445.0 1,543.5 1,652.5 7.87

Latin America


TOTAL 56.3 59.8 68.8 84.5 91.1 98.1 105.8 113.9 122.7 132.0 141.9 7.69

Asia - Pacific


TOTAL 357.5 396.9 444.1 462.4 488.8 516.7 543.9 574.3 607.3 642.0 679.4 5.65

34P3B5-54






TOTAL 619.8 767.6 890.9 941.8 990.3 1,035.3 1,081.3 1,127.3 1,172.8 1,218.6 1,263.7 4.29

Eastern Europe


TOTAL 36.6 45.9 54.9 66.0 73.7 80.9 88.0 95.1 102.0 108.5 114.7 8.21

35P3B5-54






TOTAL 16.0 18.8 21.6 22.3 23.7 25.1 26.5 28.1 29.7 31.5 33.3 5.93

WORLD TOTAL 1,855.1 2,116.2 2,375.2 2,549.6 2,756.9 2,929.0 3,105.3 3,288.9 3,479.5 3,676.2 3,885.5 6.20



The above figures indicate health care expenditure by government


36P3B5-54

Decision Support DatabaseTable Percent Healthcare Expenditure in GDP

Region / Country 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012North America

Canada 9.9 10.1 10.2 10.3 10.4 10.7 11.0 11.2 11.4 11.5 11.6United States 14.9 15.3 15.4 15.2 15.4 15.6 15.9 16.3 16.6 17.0 17.4

TOTAL 14.6 14.9 15.0 14.8 15.0 15.2 15.5 15.8 16.2 16.5 16.9

Latin America

Argentina 11.3 11.3 11.3 11.4 11.5 11.7 11.8 11.9 12.0 12.2 12.4Brazil 9.1 9.1 9.2 9.3 9.3 9.3 9.3 9.3 9.4 9.5 9.6Chile 5.8 6.0 6.1 6.4 6.4 6.5 6.5 6.5 6.6 6.7 6.7Mexico 9.2 9.4 9.4 9.4 9.6 9.8 9.9 10.1 10.3 10.5 10.7Peru 4.4 4.5 4.5 4.6 4.7 4.8 4.9 5.0 5.2 5.3 5.5Venezuela 4.9 5.5 5.5 5.6 5.7 5.7 5.8 5.8 5.9 5.9 5.9

TOTAL 8.7 8.8 8.9 9.0 9.0 9.1 9.2 9.2 9.3 9.4 9.5

Asia - Pacific

Australia 9.6 9.7 9.9 10.5 10.7 10.9 11.0 11.1 11.2 11.4 11.7China 5.7 6.0 6.0 6.1 6.4 6.6 6.8 7.0 7.1 7.3 7.5Hong Kong 5.8 6.1 6.2 6.2 6.3 6.6 6.8 6.9 7.1 7.3 7.5India 6.1 6.1 6.4 6.4 6.5 6.6 6.7 6.7 6.8 6.9 6.9Indonesia 3.7 3.4 3.4 3.5 3.5 3.5 3.6 3.7 3.8 3.9 4.0Japan 6.8 6.9 7.0 7.0 7.4 7.9 7.7 7.7 7.8 7.8 7.8Malaysia 3.8 3.9 3.9 4.0 4.1 4.3 4.4 4.6 4.7 4.8 5.0New Zealand 8.7 8.6 8.7 9.0 9.2 9.3 9.5 9.7 9.8 9.9 9.9Philippines 2.9 2.9 2.9 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.1Singapore 3.8 3.9 3.9 3.9 3.9 4.0 4.0 4.0 4.0 4.1 4.2South Korea 4.9 4.9 5.0 5.0 5.1 5.1 5.2 5.2 5.2 5.3 5.3Taiwan 6.0 6.0 6.1 6.1 6.1 6.1 6.2 6.2 6.3 6.3 6.3Thailand 5.8 5.9 5.9 6.1 6.2 6.3 6.4 6.6 6.8 7.1 7.5

TOTAL 6.4 6.5 6.6 6.6 6.8 7.1 7.0 7.1 7.2 7.2 7.3


37P3B5-54



Region / Country 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012

Western Europe

Austria 7.5 7.5 7.6 7.6 7.6 7.6 7.6 7.6 7.6 7.7 7.7Belgium 9.1 9.6 9.6 9.7 9.8 9.9 9.9 10.0 10.1 10.2 10.3Denmark 8.8 9.1 9.2 9.1 9.2 9.3 9.4 9.5 9.5 9.5 9.5Finland 7.2 7.3 7.3 7.5 7.6 7.6 7.7 7.7 7.7 7.8 7.8France 9.7 9.8 10.0 10.3 10.5 10.7 10.8 10.9 11.0 11.1 11.3Germany 10.6 10.6 10.7 10.9 11.1 11.2 11.3 11.4 11.5 11.7 11.9Greece 9.8 9.9 9.9 10.0 10.1 10.2 10.2 10.3 10.2 10.3 10.3Iceland 9.9 10.5 10.6 10.6 10.9 11.1 11.3 11.5 11.7 11.9 12.0Ireland 8.0 8.4 8.5 8.6 8.8 9.0 9.2 9.3 9.5 9.7 9.9Italy 8.4 8.3 8.3 8.4 8.4 8.4 8.4 8.5 8.5 8.5 8.5Luxembourg 6.9 6.9 7.0 7.1 7.2 7.3 7.4 7.5 7.6 7.7 7.7Netherlands 9.3 9.8 9.8 10.6 10.9 11.0 11.1 11.2 11.3 11.4 11.6Norway 9.6 10.3 10.4 10.4 10.6 10.8 11.0 11.2 11.4 11.6 11.8Portugal 9.3 9.7 9.9 10.1 10.2 10.3 10.5 10.6 10.7 10.9 11.0Spain 7.6 7.7 7.8 7.9 7.9 8.0 8.1 8.2 8.2 8.3 8.4Sweden 9.2 9.4 9.6 9.7 9.9 10.0 10.1 10.2 10.3 10.4 10.6Switzerland 11.1 11.5 11.5 11.7 11.8 11.9 12.0 12.1 12.3 12.4 12.6United Kingdom 7.7 7.8 8.0 8.2 8.4 8.6 8.8 9.0 9.2 9.3 9.5

TOTAL 9.0 9.1 9.2 9.3 9.5 9.6 9.7 9.8 9.9 10.0 10.1

Eastern Europe

Czech Republic 7.2 7.5 7.5 7.6 7.6 7.7 7.7 7.7 7.9 8.0 8.2Hungary 7.8 8.4 8.6 8.8 8.9 9.0 9.1 9.2 9.3 9.4 9.5Poland 5.9 5.9 6.0 6.0 6.0 6.1 6.3 6.4 6.5 6.6 6.6Russia 6.1 6.1 6.2 6.2 6.2 6.3 6.3 6.4 6.4 6.5 6.6Turkey 6.5 6.6 6.7 6.8 6.8 6.8 6.8 6.9 7.0 7.1 7.2

TOTAL 6.6 6.6 6.6 6.7 6.7 6.8 6.8 6.9 6.9 7.0 7.0

38P3B5-54



Region / Country 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012

Middle East & Africa

Egypt 4.9 5.0 5.0 5.1 5.1 5.2 5.2 5.2 5.2 5.3 5.3Israel 8.7 8.8 8.8 9.0 9.1 9.1 9.2 9.3 9.4 9.5 9.6Saudi Arabia 4.3 4.3 4.4 4.4 4.4 4.5 4.5 4.5 4.6 4.6 4.7South Africa 8.7 8.2 9.4 8.2 8.1 8.2 8.2 8.2 8.2 8.2 8.2

TOTAL 6.1 6.1 6.1 6.2 6.2 6.2 6.2 6.3 6.2 6.3 6.3

WORLD TOTAL 10.2 10.2 10.3 10.3 10.4 10.6 10.7 10.9 11.0 11.2 11.4


Note1. Regional and World total are calculated using weighted average of countries in the region and are not the simple average.

The above figures represent Healthcare Expenditure as percentage of Gross Domestic Product.


39P3B5-54


Decision Support DatabaseTable Population 65 Plus (Mn)



Canada 4.1 4.2 4.2 4.3 4.4 4.5 4.6 4.7 4.9 5.0 5.2 2.66United States 35.6 35.9 36.3 36.7 37.2 37.9 38.7 39.5 40.2 41.1 42.6 2.14

TOTAL 39.7 40.1 40.5 41.0 41.6 42.4 43.3 44.2 45.1 46.1 47.7 2.19

Latin America


TOTAL 22.9 23.7 24.5 25.3 26.1 27.0 27.9 28.8 29.8 30.8 31.9 3.40

Asia - Pacific


TOTAL 193.8 199.2 204.3 209.6 215.4 221.4 227.1 233.2 239.4 246.0 254.0 2.79

40P3B5-54




(2005 - 2012)

Western Europe


TOTAL 65.4 66.4 67.4 68.4 69.3 70.0 70.8 71.7 72.4 73.3 74.6 1.24

Eastern Europe

Czech Republic 1.4 1.4 1.4 1.5 1.5 1.5 1.5 1.6 1.6 1.7 1.7 2.64Hungary 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.6 1.6 1.6 1.6 0.86Poland 4.9 5.0 5.0 5.1 5.1 5.1 5.2 5.2 5.2 5.3 5.4 0.83Russia 18.8 19.3 19.8 20.3 20.6 20.8 20.4 19.8 19.2 18.8 18.9 (1.38)Turkey 4.2 4.4 4.5 4.7 4.8 4.9 5.1 5.2 5.3 5.5 5.6 2.54

TOTAL 30.8 31.6 32.3 33.0 33.5 33.9 33.7 33.3 32.9 32.8 33.2 (0.14)

41P3B5-54






TOTAL 6.4 6.6 6.7 6.9 7.1 7.4 7.6 7.8 8.0 8.3 8.6 3.09

WORLD TOTAL 358.9 367.4 375.7 384.3 393.1 402.0 410.3 418.9 427.6 437.4 450.1 2.28


The above figures represent total midyear population aged 65 years and above


42

About Frost & Sullivan

43P3B5-54

Who is Frost & Sullivan

The Growth Partnership Company

• Founded in 1961, Frost & Sullivan has over 45 years of assisting clients with their decision-making

and growth issues.

• Over 1,700 Growth Consultants and Industry Analysts across 32 global locations

• Over 10,000 clients worldwide - emerging companies, the global 1000 and the investment community

• Developers of the Growth Excellence Matrix – industry leading growth positioning tool for corporate

executives

• Developers of TEAM Methodology, proprietary process to ensure that clients receive a 360o

perspective of technology, markets and growth opportunities

• Three core services: Growth Partnership Services, Growth Consulting and Career Best

Practices

44P3B5-54

What Makes Us Unique

Exclusively Focused on Growth

Global thought leader exclusively focused on addressing client growth strategies and plans – Team actively engaged in researching and developing of growth models that enable clients to achieve aggressive growth objectives.

Industry Breadth

Cover the broad spectrum of industries and technologies to provide clients with the ability to look outside the box and discover new and innovative ideas.

Global Perspective

32 global offices ensure that clients receive a global coverage/perspective based on regional expertise.

360o Perspective

Proprietary TEAM Methodology integrates all 6 critical research methodologies to significantly enhance the accuracy of decision making and lower the risk of implementing growth strategies.

Growth Monitoring

Continuously monitor changing technology, markets and economics and proactively address clients growth initiatives and position.

Trusted Partner

Working closely with client Growth Teams – helping them generate new growth initiatives and leverage all of Frost & Sullivan assets to accelerate their growth.

45P3B5-54

TEAM Methodology

Frost & Sullivan’s proprietary TEAM methodology, ensures that clients have complete “360 Degree

Perspective” from which to drive decision-making. Technical, Econometric, Application, and Market

information ensures that clients have a comprehensive view of industries, markets and technology.

Technical Real-time intelligence on technology, including emerging technologies, new

R&D breakthroughs, technology forecasting, impact analysis, groundbreaking

research, and licensing opportunities.

Econometric In-depth qualitative and quantitative research focused on timely and critical

global, regional, and country specific trends, including the political,

demographic, and socioeconomic landscapes.

Application Insightful strategies, networking opportunities, and best practices that can be

applied for enhanced market growth; interactions between the client, peers, and

Frost & Sullivan representatives that result in added value and effectiveness.

Market Global and regional market analysis, including drivers and restraints, market

trends, regulatory changes, competitive insights, growth forecasts, industry

challenges, strategic recommendations, and end-user perspectives.

46P3B5-54

Global Perspective

• 1,700 staff across every major market worldwide

• Over 10,000 clients worldwide from emerging to global 1000 companies

Asia Pacific : Japan Healthcare Outlook 2010

Health & Medicine

Transcript of Asia Pacific : Japan Healthcare Outlook 2010